Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02972632 · ClinicalTrials.gov registry record · Phase 4
Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder
A Phase 4 study of Major Depressive Disorder, sponsored by Takeda.
- Completed
- Registry status
- Phase 4
- Development phase
- 123
- Enrollment target
- 20
- Study locations
NCT02972632 is a Phase 4 study of Major Depressive Disorder that has completed, run by Takeda. The registered enrollment target is 123 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT02972632, a Phase 4 study of Major Depressive Disorder, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 123 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the effectiveness of treatment with vortioxetine on participant goal achievement after a change in antidepressant medication for the treatment of major depressive disorder (MDD).
Conditions Studied
Interventions
- DRUG Vortioxetine
Study Locations (20)
California
- ATP Clinical Research, Inc. - Costa Mesa
- ProScience Research Group - Culver City
- Behavioral Research Specialists, LLC - Glendale
- Pacific Research Partners - Oakland
- Excell Research - Oceanside
- Anderson Clinical Research - Redlands
- University Medical Group - Upland
Florida
- Suncoast Clinical Research Inc. - New Port Richey
- Behavioral Clinical Research , Inc - North Miami
- Compass Research Main - Orlando
- University of South Florida - Tampa
Illinois
- Great Lakes Clinical Trials - Chicago
- Baber Research Group - Naperville
Massachusetts
- Novex Clinical Research, LLC - New Bedford
- Coastal Research Associates, Inc. - South Weymouth
Colorado
- MCB Clinical Research Centers, LLC - Colorado Springs
Indiana
- Deaconess Clinic - Evansville
Michigan
- University of Michigan, Ann Arbor - Ann Arbor
New York
- Columbia University Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2016-12-22 |
| Est. Completion | 2018-02-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02972632
The ClinicalTrials.gov registry entry for NCT02972632 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (67% lower). The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which Vortioxetine is the first listed.
NCT02972632 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT02972632 about?
NCT02972632 is a clinical study titled "Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder". The purpose of this study is to determine the effectiveness of treatment with vortioxetine on participant goal achievement after a change in antidepressant medication for the treatment of major depressive disorder (MDD).
What is the current status of trial NCT02972632?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 123 participants. The study started on 2016-12-22. Estimated completion is 2018-02-06.
What conditions does trial NCT02972632 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT02972632?
The interventions under investigation include: Vortioxetine (DRUG).
Who is sponsoring clinical trial NCT02972632?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02972632 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
RECRUITING · Phase 4
-
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
RECRUITING · Phase 4
-
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
RECRUITING · Phase 4
-
Neural Circuit Effects of Ketamine in Depression
RECRUITING · Phase 4
-
Aβ Dynamics in LLMD
RECRUITING · Phase 4
-
Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.